The Progranulin HTRF kit is designed for the accurate quantitative measurement of Progranulin produced by cells.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein Quantification |
Sample Volume | 16 µL |
The Progranulin HTRF kit is designed for the accurate quantitative measurement of Progranulin produced by cells.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Progranulin, also called proepithelin or prostate cancer (PC) cell-derived growth factor, is the precursor protein of granulin. Progranulin is involved in Frontotemporal Lobar Degeneration (FTLD) and Alzheimer's Disease, where it may protect against beta amyloid toxicity. This cell-based HTRF assay ensures quick results, and is adapted to the functional screening of compounds using progranulin secreting cells.
Application |
Protein Quantification
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Kit
|
Sample Volume |
16 µL
|
Shipping Conditions |
Shipped in Dry Ice
|
Target Class |
Biomarkers
|
Target Species |
Human
|
Technology |
TR-FRET
|
Unit Size |
500 Assay Points
|
Human Progranulin is measured using a sandwich immunoassay involving two specific anti-human Progranulin antibodies, respectively labelled with Terbium Cryptate (donor) and d2 (acceptor). The intensity of the signal is proportional to the concentration of the Progranulin present in the sample.
The simple Progranulin assay protocol, using a 384-well small volume white plate (20 µL final), is described on the right. Cell supernatant, sample, or standard is dispensed directly into the assay plate for the detection of human Progranulin. The antibodies labelled with the HTRF donor and acceptor may be pre-mixed and added in a single dispensing step to further streamline the assay procedure. The assay can be run in 96- to 384-well plates by simply resizing each addition volume proportionally.
Intra-assay (n=24)
Sample | Mean [Progranulin] (pg/mL) | CV | ||
---|---|---|---|---|
1 | 781 | 2.1% | ||
2 | 3,125 | 2.1% | ||
3 | 6.250 | 1.4% | ||
4 | 25,000 | 1.2% | ||
5 | 50,000 | 1.2% | ||
|
1.6% |
Inter-assay (n=4)
Sample | Mean [Progranulin] (pg/mL) | CV | ||
---|---|---|---|---|
1 | 777 | 11% | ||
2 | 1,787 | 12% | ||
3 | 4,109 | 13% | ||
4 | 21,739 | 10% | ||
5 | 50,000 | 8% | ||
|
11% |
Dilution factor | [Progranulin] expected (pg/mL) | [Progranulin] detected (pg/mL) | Recovery |
---|---|---|---|
1 | - | 42,602 | - |
2 | 21,301 | 21,100 | 99% |
4 | 10,650 | 10,524 | 99% |
8 | 5,325 | 5,023 | 94% |
16 | 2,663 | 2,711 | 102% |
32 | 1,331 | 1,398 | 105% |
64 | 666 | 707 | 106% |
Mean | 101% |
The excellent recovery % obtained from these experiments show the good linearity of the assay.
Sample | [Progranulin] added (pg/mL) | [Progranulin] expected (pg/mL) | [Progranulin] detected (pg/mL) | Recovery |
---|---|---|---|---|
1 1,419 pg/mL |
492 | 1,911 | 1,788 | 97% |
2,199 | 3,618 | 3,339 | 92% | |
11,139 | 12,558 | 12,187 | 97% | |
2 4,440 pg/mL |
492 | 4,932 | 4,850 | 98% |
2,199 | 6,639 | 6,285 | 95% | |
11,139 | 15,579 | 16,201 | 104% | |
3 19,493 pg/mL |
492 | 19,985 | 19,703 | 99% |
2,199 | 21,692 | 21,490 | 99% | |
11,139 | 30,632 | 32,267 | 105% |
The same amount of recombinant protein was added to 3 different serum samples, and the set of responses obtained from a standard curve was compared to the calculated expected values. The ~ 100% of recovery found validates the sample matrix used for this assay.
iPSC-Microglia were derived as in McQuade et al. 2018. iPS-Microglia were stimulated with 10 ng / mL cytokines for 24 hours in the absence of TGF-b1. Cell supernatants were collected, and secreted levels of Progranulin were measured following the procedure given in the HTRF kit package insert. In agreement with the literature, IFN-γ + IL-1b (pro-inflammatory) treated microglial cells displayed a decreasing progranulin release trend, whereas anti-inflammatory IL-4 and IL-13 Th2 cytokines displayed a significant increase in secreted progranulin.
Data kindly provided by Amanda McQuade and Dr. Mathew Blurton-Jones (University of California, Irvine)
Are you looking for resources, click on the resource type to explore further.
Emerging pathways to neuroinflammation and neurodegeneration
Neurodegenerative diseases, such as amyotrophic lateral sclerosis...
This guide provides you an overview of HTRF applications in several therapeutic areas.
We are here to answer your questions.